Cambridge Healthtech Institute’s 8th Annual

Optimizing Biologics Formulation and Stability

New Technologies, Case Studies, and Research Updates on Development of Novel Biologics

August 26-27, 2020

 

The eighth annual Optimizing Biologics Formulation and Stability conference will cover latest trends and challenges in formulations development of novel biologic formats, process optimization, manufacturing, and device and packaging considerations for existing and emerging protein therapeutics. This year’s conference will also discuss the role of machine learning and automation in formulation screening and development. We are seeking case studies, especially unpublished and innovative work on co-formulation, formulation of novel biologics, development and delivery of high-concentration protein formulations, effective scale-up strategies, excipient-induced instability, process challenges, fill-finish challenges, and predictive tools for rapid formulation and stability screening.

Preliminary Agenda

INDUSTRY PERSPECTIVE ON FORMULATION DEVELOPMENT: NEW MODALITIES, NEW CHALLENGES

Formulation Strategies for Emerging Drug Product Modalities: A Renaissance for Biotech Formulation Science

Mark Brader, PhD, Research Fellow, Moderna, Inc.

Implementing Internal Formulation Development for Antibodies and ADCs: Lessons Learned from a Biotech Company

Ryan Knihtila, PhD, Scientist II, Formulation and Analytical Sciences, Magenta Therapeutics

Industry Perspective on Challenges of Using Closed System Transfer Devices with Biological Products

Sanket Patke, PhD, Senior Scientist, Biologics Drug Product Development, Sanofi

PROCESS AND FILL-FINISH CONSIDERATIONS

Post-Approval Implementation of Frozen Drug Substance Process – Challenges and Opportunities

Rong Li, PhD, Associate Director, MSAT, Sanofi

HIGH-CONCENTRATION AND HIGH-VISCOSITY FORMULATIONS

Nanoparticle and Microparticle Formulations of Peptides, Oligonucleotides, and Proteins by Inverse Flash NanoPrecipitation

Robert Pagels, PhD, Director of Research and Development, Optimeos Life Sciences

Microfluidics: An Advanced Platform for Pharmaceutical Protein Formulation

Sabirudiin Mirza, PhD, Senior Research Fellow, School of Engineering and Applied Science, Harvard University

APPLICATION OF ARTIFICIAL INTELLIGENCE, MACHINE LEARNING AND AUTOMATION IN FORMULATION DEVELOPMENT

Leveraging Automation to Enable High-Concentration Formulation Development

Peter Soler, PhD, Senior Research Investigator, Bristol-Myers Squibb, Co.

Strategies to Design and Create a High-Throughput Automation Lab for Large-Molecule Biologics Formulation Development

Alex Chin, Senior Scientist, Merck & Co., Inc.

Automated Forced Degradation of Therapeutic Proteins

Nathan Heacock, Scientist, Biopharm Product Sciences, Biopharm R&D, GlaxoSmithKline

Application of Machine Learning to Predict Monomer Retention of Therapeutic Proteins after Long-Term Storage

Gentiluomo Lorenzo, PhD, Scientist, R&D, Coriolis Pharma Research

Utilizing Machine Learning/Systems Biology from Process Development through Commercialization

Gaurav Chauhan, MS, Associate Principal Scientist, Biologics Process Research and Development, Merck & Co., Inc.




For more details on the conference, please contact:
Nandini Kashyap, MPharm
Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-972-5406
Email: nkashyap@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359
Email: sjohnson@healthtech.com

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: ccooke@healthtech.com



Premier Sponsors:

Fujifilm-Diosynth-Logo

NanotemperTechnologies

Samsung_Biologics

UnchainedLabs
Vironova